Bio

Prof. Leszek Lisowski, PhD, MBA is Co-Founder and Chief Technology Officer of Nionyx Bio, where he leads the company’s next-generation AAV capsid engineering and translational vectorology programs. He brings more than 20 years of experience in vectorology, with a career spanning world-class academic research institutions, philanthropic organisations and industry, focused on the design and manufacture of viral vectors for human gene therapy.

Prof. Lisowski earned his PhD in Molecular Biology and Genetics in the laboratory of Prof. Michel Sadelain at Memorial Sloan Kettering Cancer Center / Cornell University, followed by postdoctoral training with Prof. Mark Kay at Stanford University School of Medicine, where he pioneered work in AAV evolution and retargeting. He went on to lead the Gene Transfer, Targeting and Therapeutics (GT3) Facility at the Salk Institute for Biological Studies, co-founded LogicBio Therapeutics, and later established the Vector and Genome Engineering Facility and his independent research group, Translational Vectorology Research Unit, at Children’s Medical Research Institute (CMRI) in Sydney.

In addition to his role at Nionyx Bio, Prof. Lisowski is a Unit Head at CMRI, a Conjoint Professor at the University of Sydney, Visiting Professor at Military Institute of Medicine, in Warsaw, Poland and holds an Honorary Faculty status at University College London. He also has an MBA. from the University of California, San Diego.